Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06003270 · ClinicalTrials.gov registry record · Phase 2
Biological Effects of Quercetin in COPD Phase II
A Phase 2 study of Chronic Obstructive Pulmonary Disease and Emphysema, sponsored by Temple University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06003270: Recruiting Phase 2 study of Chronic Obstructive Pulmonary Disease and Emphysema, sponsored by Temple University.
NCT06003270 is a Phase 2 study of Chronic Obstructive Pulmonary Disease and Emphysema that is actively recruiting participants, run by Temple University. The registered enrollment target is 30 participants, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06003270, a Phase 2 study of Chronic Obstructive Pulmonary Disease and Emphysema, is actively recruiting participants, sponsored by Temple University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study determines whether quercetin supplementation reduces the inflammation and oxidative stress markers in patients with chronic obstructive pulmonary disease. It is small study with 8 subjects receiving quercetin 1000 mg/day, 8 patients receiving 500 mg/day and 4 subjects receive placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Quercetin 1000 mg
- DRUG Quercetin 500 MG
Study Locations (1)
Pennsylvania
- Nathaniel Marchetti - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2025-07-31 |
| Phase | Phase 2 |
What NCT06003270 shows while recruiting
NCT06003270 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06003270 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06003270 about?
NCT06003270 is a clinical study titled "Biological Effects of Quercetin in COPD Phase II". This study determines whether quercetin supplementation reduces the inflammation and oxidative stress markers in patients with chronic obstructive pulmonary disease. It is small study with 8 subjects receiving quercetin 1000 mg/day, 8 patients receiving 500 mg/day and 4 subjects receive placebo.
What is the current status of trial NCT06003270?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-11-01. Estimated completion is 2025-07-31.
What conditions does trial NCT06003270 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis With Airway Obstruction.
What interventions are being tested in trial NCT06003270?
The interventions under investigation include: Placebo (DRUG), Quercetin 1000 mg (DRUG), Quercetin 500 MG (DRUG).
Who is sponsoring clinical trial NCT06003270?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06003270 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06003270's enrollment target sits among peer trials
30 67th of 86 higher than 16 of 86 other Chronic Obstructive Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
RECRUITING · Phase 2
-
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
RECRUITING · Phase 2
-
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
RECRUITING · Phase 2
-
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
RECRUITING · Phase 2
-
Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD
RECRUITING · Phase 2
-
A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI